Biotech Is Getting A Big Boost Following Clinton's Loss

Investors in biotech stocks were getting a little weary leading up to the Presidential elections. However, with the results in favor of Donald Trump, biotech stocks are trading higher.

Some of the stocks are gaining significantly in Wednesday's pre-market session. Clinton was not happy with drug pricing by pharmaceutical firms, and many feared of the price cuts and regulations her presidency might bring to the table.

The following stocks gained in the pre-market trading on Wednesday:

• SPDR S&P Biotech (ETF) XBI trading up 4.8 percent to $60.60
• iShares NASDAQ Biotechnology Index (ETF) IBB added 4.33 percent to $272.96.
• Valeant Pharmaceuticals Intl Inc VRX, which tanked 21.69 percent on Tuesday, gained 1.13 percent to $15.15.
• Mylan NV MYL jumped 5.85 percent to $39.28.
• Pfizer Inc. PFE advanced 7.33 percent to $32.25.
• Eli Lilly and Co LLY gained 3.01 percent to $76.25.
• Amgen, Inc. AMGN was up 2.82 percent to $142.35.
• Gilead Sciences, Inc. GILD added 1.94 percent to $75.50.
• Merck & Co., Inc. MRK gained 2.88 percent to $62.25.
• Novartis AG (ADR) NVS advanced 2.41 percent to $73.00.